Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.53 USD | +2.43% | +2.43% | +54.27% |
Apr. 02 | Cannabis Stocks Rise Pre-Bell After Florida Supreme Court Allows Ballot Initiative to Legalize Marijuana | MT |
Apr. 02 | Pot producers climb as recreational cannabis to go on Florida ballot | RE |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+54.27% | 666M | D+ | ||
+33.43% | 700B | C+ | ||
+26.43% | 569B | B | ||
-5.12% | 358B | C+ | ||
+19.59% | 330B | B- | ||
+4.89% | 287B | C+ | ||
+14.32% | 236B | B+ | ||
+5.79% | 202B | B- | ||
-9.49% | 197B | A+ | ||
+4.26% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SNDL Stock
- Ratings SNDL Inc.